293.17 USD
↘ 0.89 (0.30%)AT CLOSE (11:59 AM EDT)
Alnylam Pharmaceuticals, Inc.
ALNYNASDAQ • USD
289.33
↘ 3.84 (1.31%)
POST MARKET (AS OF 07:25 PM EDT)
Post Market
AS OF 07:25 PM EDT
289.33
↘ 3.84 (1.31%)
Market: CLOSED
Alnylam Pharmaceuticals, Inc. (ALNY) trades at $293.24 per share. The technical outlook is "Neutral" and the fundamental picture shows "Buy". This is driven by a robust Altman Z-Score, exceptional Return on Equity (53.7%) and a bearish Death Cross on the long-term moving averages. On the valuation front, ALNY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 25, 2026.
Open?$293.68
High?$298.35
Low?$290.07
Prev. Close?$294.06
Volume?1.1M
Avg. Volume?1.1M
VWAP?$292.86
Rel. Volume?1.00x
Bid / Ask
Bid?$273.00 × 40
Ask?$299.55 × 320
Spread?$26.55
Midpoint?$286.28
Valuation & Ratios
Market Cap?39.1B
Shares Out?133.5M
Float?132.4M
Float %?99.9%
P/E Ratio?67.81
P/B Ratio?36.40
EPS?$4.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Themes
Employees
2.5K
Market Cap
39.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2004-05-28
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?100
Momentum?62
Short Sent.?49
Piotroski F-Score?5/9Mixed
Altman Z-Score?6.03Safe
Confidence?69%Moderate
Short InterestModerate
Short % of Float?4.11%Low
Short Interest?5.4M
Days to Cover?4.8
Free Float132.4M
Avg Daily Volume1.1M
Settlement Date2026-06-15
Financial Health
Current Ratio?3.13Strong
Quick Ratio?3.06Strong
Cash Ratio?1.27Strong
Debt/Equity?0.94Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?67.8PRICEY▾
Peers100
S&P7
P/B?36.40HIGH▾
Peers100
S&P3
P/S?9.13HIGH▾
Peers100
S&P9
P/FCF?61.0PRICEY▾
Peers100
S&P7
EV/EBITDA?47.6HIGH▾
Peers100
S&P3
EV/Sales?8.97HIGH▾
Peers100
S&P14
Returns & Efficiency
ROE?53.7%STRONG▾
Peers50
S&P92
ROA?11.3%STRONG▾
Peers50
S&P78
Cash Flow & Enterprise
FCF?$641.3M
Enterprise Value?$38.4B
Fundamentals ratios updated end of day